256 related articles for article (PubMed ID: 21180305)
1. Beta blockers & left ventricular hypertrophy regression.
George T; Ajit MS; Abraham G
Indian Heart J; 2010; 62(2):139-42. PubMed ID: 21180305
[TBL] [Abstract][Full Text] [Related]
2. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
Schneider MP; Klingbeil AU; Delles C; Ludwig M; Kolloch RE; Krekler M; Stumpe KO; Schmieder RE
Hypertension; 2004 Jul; 44(1):61-6. PubMed ID: 15184349
[TBL] [Abstract][Full Text] [Related]
3. Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch.
Benedetto U; Melina G; Refice S; di Bartolomeo R; Roscitano A; Angeloni E; Sinatra R
Ann Thorac Surg; 2010 Dec; 90(6):1899-903; discussion 1903. PubMed ID: 21095333
[TBL] [Abstract][Full Text] [Related]
4. Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Krauser DG; Devereux RB
Herz; 2006 Jun; 31(4):305-16. PubMed ID: 16810470
[TBL] [Abstract][Full Text] [Related]
5. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
[TBL] [Abstract][Full Text] [Related]
6. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
8. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; López B; Edner M; González A; Díez J; Malmqvist K
J Hypertens; 2007 Sep; 25(9):1958-66. PubMed ID: 17762662
[TBL] [Abstract][Full Text] [Related]
9. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Zeller A; Battegay E
Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
[TBL] [Abstract][Full Text] [Related]
10. Treatment of diastolic dysfunction in hypertensive left ventricular hypertrophy.
Bella JN
Am J Hypertens; 2006 Sep; 19(9):937-8. PubMed ID: 16942936
[No Abstract] [Full Text] [Related]
11. The importance of left ventricular hypertrophy in human hypertension.
Kahan T
J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
[TBL] [Abstract][Full Text] [Related]
12. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
Ovchinnikov AG; Serbul VM; Ageev FT
Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
[TBL] [Abstract][Full Text] [Related]
13. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
[TBL] [Abstract][Full Text] [Related]
15. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
[TBL] [Abstract][Full Text] [Related]
16. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
[TBL] [Abstract][Full Text] [Related]
17. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Mörtsell D; Malmqvist K; Held C; Kahan T
J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
[TBL] [Abstract][Full Text] [Related]
18. Effect of atenolol and ramipril on regression of left ventricular hypertrophy: comparative echocardiographic assessment.
Rosatti F; Lunardi M; Mangrella M; Filippelli A; Lampa E; Rossi F
Adv Ther; 1995; 12(2):147-55. PubMed ID: 10150325
[TBL] [Abstract][Full Text] [Related]
19. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
Friedrich MG; Dahlöf B; Sechtem U; Unger T; Knecht M; Dietz R;
J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):234-43. PubMed ID: 14689371
[TBL] [Abstract][Full Text] [Related]
20. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Thürmann PA; Kenedi P; Schmidt A; Harder S; Rietbrock N
Circulation; 1998 Nov; 98(19):2037-42. PubMed ID: 9808602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
